Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Does lipitor's effectiveness decrease with high fat meals?Patent tenofovir alafenamide gilead?How does renal function impact tigecycline's liver safety?Dabrafenib and trametinib price?Mebendazole ingredients?
See the DrugPatentWatch profile for symbicort
Symbicort (budesonide/formoterol) was first approved in the United States in 2009.[1]
Approval dates can differ by country and by product version (brand vs. generic). If you tell me the country (or whether you mean when it launched, when generics entered, or when your specific inhaler strength was approved), I can pin down the correct year.
Symbicort is an inhaler that combines an inhaled corticosteroid (budesonide) with a long-acting bronchodilator (formoterol).[1] Sources: [1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021929
Other Questions About Symbicort :